2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1050

Population-Based Analysis Of Treatment Patterns For Recently Diagnosed Rheumatoid Arthritis Patients In The United States
Abstract Number: 2233

Porphyromonas Gingivalis peptidylarginine Deiminase Exacerbates Collagen-Induced Arthritis In C57BL/6 mice
Abstract Number: 2222

Positive Allosteric Modulation Of The Adenosine A_2a Receptor Alters Inflammatory Cytokine Production and Alleviates Chronic Arthritis In Rats
Abstract Number: 2363

Positivity Of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Is Associated With The Response Rate Of Infliximab, But Not Tocilizumab, In Treatment Of Rheumatoid Arthritis
Abstract Number: 229

Positron Emission Tomography Assessment Of Children With Systemic-Onset Juvenile Idiopathic Arthritis
Abstract Number: 445

Post-Hoc Analysis Of Serious Infection Events and Selected Clinical Factors In Rheumatoid Arthritis Patients Treated With Tofacitinib
Abstract Number: 1605

Post-Marketing Experience With Belimumab In U.S. Lupus Centers: Data From The Lupus Clinical Trials Consortium, Inc. (LCTC) National Patient Registry
Abstract Number: 2322

Post–Hoc Analysis Showing Better Clinical Response With The Loading Dose Of Certolizumab Pegol In Japanese Patients With Active Rheumatoid Arthritis
Abstract Number: 117

Postmenopausal Hormone Therapy and The Risk Of Rheumatoid Arthritis: Results From The Swedish EIRA Study
Abstract Number: 113

Posttraumatic Stress Disorder and Risk For Incident Rheumatoid Arthritis
Abstract Number: 1876

Potential Chondrogenic Biomarkers For Cell-Based Therapy Monitoring In Osteoarthritis
Abstract Number: 643

Potential Immunopathological Roles Of The Novel Anti-Inflammatory Cytokine Interleukin-35 In Patients With Systemic Lupus Erythematous
Abstract Number: 2877

Potential Of Integrating Human Genetics and Electronic Medical Records For Drug Discovery: The Example Of TYK2 and Rheumatoid Arthritis
Abstract Number: 1856

Potentiating Effects Of IL-17A, IL-17AF, IL-17F In Combination With TNF But Not With IL-1beta In Human Primary Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
Abstract Number: 1948

Power Doppler Ultrasound 7-Joint Score Vs. Simplified Disease Activity Index In Rheumatoid Arthritis Associated With Fibromyalgia

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].